Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067) Meeting Abstract

  


Authors: Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M. S.; Wolter, P.; Lebbe, C.; Schachter, J.; Thomas, L.; Hassel, J. C.; Lorigan, P.; Walker, D.; Jiang, J.; Hodi, F. S.; Wolchok, J. D.
Abstract Title: Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)
Meeting Title: 32. Deutscher Krebskongress Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ (DKK 2016)
Journal Title: Oncology Research and Treatment
Volume: 39
Issue: Suppl. 1
Meeting Dates: 2016 Feb 24-27
Meeting Location: Berlin, Germany
ISSN: 2296-5270
Publisher: S. Karger AG  
Date Published: 2016-02-01
Start Page: 40
Language: English
ACCESSION: WOS:000371353700124
PROVIDER: wos
Notes: Meeting Abstract: ID 0354 -- [32nd German Cancer Congress – Cancer Medicine Today: Preventive, Personalized, Precise and Participative] -- Source: Wos